Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7595397 Compounds which modulate the CB2 receptor

Patent 7595397 was granted and assigned to Boehringer Ingelheim on September, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Boehringer Ingelheim

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

75953970

Patent Inventor Names

Eugene Richard Hickey0

David S. Thomson0

Doris Riether0

Renee Zindell0

Innocent Mushi0

Monika Ermann0

Date of Patent

September 29, 2009

Patent Application Number

116085370

Date Filed

December 8, 2006

Patent Citations Received

‌

US Patent 12134620 Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

‌

US Patent 11878985 Substituted quinazolines as inhibitors of KRAS G12C

Patent Primary Examiner

‌

Rei Tsang Shiao

Patent abstract

Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7595397 Compounds which modulate the CB2 receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API